A rationale for treatment of endothelial dysfunction in hypertension

Journal of Hypertension, Supplement

Volumn 17, Issue 1, 1999, Pages

  Ruschitzka, Frank ^a   Corti, Roberto ^a   Noll, Georg ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Endothelin 1; Endothelium; Hypertension; Nitric oxide

Indexed keywords

ANGIOTENSIN; BRADYKININ; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; NITRIC OXIDE; PROSTACYCLIN; VASOACTIVE AGENT; VASODILATOR AGENT;

BLOOD CELL; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL FUNCTION; CELL GROWTH; CONFERENCE PAPER; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HYPERTENSION; LEUKOCYTE MIGRATION INHIBITION TEST; MUSCLE FUNCTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CELL DIVISION; DRUG THERAPY, COMBINATION; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; NITRIC OXIDE; VASODILATION; VASODILATOR AGENTS;

EID: 0033013924     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (161)

1. Lüscher TF. The endothelium. Target and promotor of hypertension? Hypertension 1990; 15:482-485.
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
3. Furchgott RF, Zawadzki J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
4. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92:652-662.
5. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88:2510-2516.
6. Zeiher AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995; 92:1094-1100.
7. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterol-aemia. Lancet 1992; 340:1430-1432.
8. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338:1546-1550.
9. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90:1248-1253.
10. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91:1981-1987.
11. Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, et al. Menopause is associated with endothelial dysfunction in women. Hypertension 1996; 28:576-582.
12. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21:929-933.
13. Taddei S, Virdis A, Mattei P, Ghiadoni L, Fasolo CB, Sudano I, et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 1997; 29:736-743.
14. Vallance P, Calver A, Collier J. The vascular endothelium in diabetes and hypertension. J Hypertens 1992; 10 (suppl 1):S25-S29.
15. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
16. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86:3375-3378.
17. Blot S, Arnal J F, Xu Y, Gray F, Michel JB. Spinal cord infarcts during long-term inhibition of nitric oxide synthase in rats. Stroke 1994; 25:1666-1673.
18. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-666.
19. Moncada S. The 1991 Ulf von Euler Lecture. The L-arginine: nitric oxide pathway. Acta Physiol Scand 1992; 145:201-227.
20. Lüscher TF. Heterogeneity of endothelial dysfunction in hypertension. Eur Heart J 1992; 13 (suppl D):50-55.
21. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, et al. Pressor effects of circulating endotholin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85:9797-9800.
22. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi, M, Masaki T. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 1989; 264:14954-14959.
23. Shinmi O, Kimura S, Sawamura T, Sugita Y, Yoshizawa T, Uchiyama Y, et al. Endothelin-3 is a novel neuropeptide; isolation and sequence determination of endothelin-1 and endothelin-3 in porcine brain. Biochem Biophys Res Commun 1989; 164:537-593.
24. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85:587-590.
25. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995 270:15262-15268.
26. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, de Wit D, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 78:473-485.
27. Shimada K, Matsushita Y, Wakabayashi K, Takahashi M, Matsubara A, lijima Y, et al. Cloning and functional expression of human endothelin-converting enzyme cDNA. Biochem Biophys Res Commun 1995; 207:807-812.
28. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348:732-735.
29. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:730-732.
30. Wright CE, Fozard JR. Regional vasodilation is a prominent feature of the haemodynamic response to endothelin in anaesthetized, spontaneously hypertensive rats. Eur J Pharmacol 1988; 155:201-203.
31. Kiowski W, Lüscher TF, Linder L, Buhler FR. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991; 83:469-475.
32. Hu RM, Levin ER, Pedram A, Frank HJL. Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells: mediation through the C receptor. J Biol Chem 1992; 267:17384-17389.
33. Lüscher TF. The endothelium and cardiovascular disease - a complex relation [editorial]. N Engl J Med 1994; 330:1081-1083.
34. Lüscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8:344-348.
35. Dohi Y, Thiel MA, Buhler FR, Lüscher TF. Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension 1990; 16:170-179.
36. Diederich D, Yang ZH, Buhler FR, Lüscher TF. Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol 1990; 258:H445-H451.
37. Dohi Y, Criscione L, Lüscher TF. Renovascular hypertension impairs formation of endothelium-derived relaxing factors and sensitivity to endothelin-1 in resistance arteries. Br J Pharmacol 1991; 104:349-354.
38. Lüscher TF. The endothelium in hypertension: bystander, target or mediator? J Hypertens 1994; 12 (suppl 10):S105-S116.
39. Kung CF, Lüscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995; 25:194-200.
40. Lüscher TF, Vanhoutte PM, Raji L. Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension 1987; 9(6 Pt 2):III1 93-III1 97.
41. Tschudi MR, Criscione L, Lüscher TF. Effect of aging and hypertension on endothelial function of rat coronary arteries. J Hypertens 1991; 9 (suppl 6):S164-S165.
42. Lüscher TF. Endothelium-derived nitric oxide: the endogenous nitrodilator in the human cardiovascular system. Eur Heart J 1991; 12 (suppl E):2-11.
43. Nava E, Noll G, Lüscher TF. Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation 1995; 91:2310-2313.
44. Tschudi MR, Noll G, Arnet U, Novosel D, Ganten D, Lüscher TF. Alterations in coronary artery vascular reactivity of hypertensive Ren-2 transgenic rats. Circulation 1994; 89:2780-2786.
45. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; ii:997-1000.
46. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Lüscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91:1314-1319.
47. Moreau P, Takase H, Kung CF, van Rooijon MM, Schaffner T, Lüscher TF. Structure and function of the rat basilar artery during chronic nitric oxide synthase inhibition. Stroke 1995; 26:1922-1928; discussion, 1928-1929.
48. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991; 17:187-193.
49. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994; 74:349-353.
50. Hishikawa K, Lüscher TF. Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation 1997; 96:3610-3616.
51. Noll G, Tschudi M, Nava E, Lüscher TF. Endothelium and high blood pressure. Int J Microcirc Clin Exp 1997; 17:273-279.
52. Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau P, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998; 101:1530-1537.
53. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endotholial superoxide anion production. J Clin Invest 1993; 91:2546-2551.
54. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988; 77:43-52.
55. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991; 88:10045-10048.
56. Lüscher TF. In: Vanhoutte PM (editor): Relaxing and contracting factors: biological and clinical research. Clifton, NJ: Humana Press; 1988. pp. 495-509.
57. Lüscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension 1987; 9:157-163.
58. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24:183-188.
59. Schiffrin EL, Sventek P, Li JS, Turgeon A, Reudelhuber T. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol 1995; 115:1377-1381.
60. Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365:759-761.
61. Donckier JE, Massart PE, Hodeige D, Van Mechelon H, Clozel JP, Laloux O, et al. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Circulation 1997; 96:1250-1256.
62. Li JS, Schiffrin EL. Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. J Hypertens 1995; 13:647-652.
63. Kitamura K, Tanaka T, Kato J, Ogawa T, Eto T, Tanaka K. Immunoreactive endothelin in rat kidney inner medulla; marked decrease in spontaneously hypertensive rats. Biochem Biophys Res Commun 1989; 162:38-44.
64. Stasch JP, Hirth-Dietrich C, Frobel K, Wegner M. Prolonged endothelin blockade reduces hypertension and cardiac hypertrophy in SHR-SP. J Cardiovasc Pharmacol 1995; 26 (suppl 3):S436-S438.
65. Chillon JM, Heistad DD, Baumbach GL. Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension 1996; 27:794-798.
66. Hocher B, Liefeldt L, Thone-Reinoke C, Orzechowski HD, Distler A, Bauer C, et al. Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 1996; 28:196-201.
67. Kurihara Y, Kurihara H, Suzuki T, Kodama K, Maemura R, Nagai H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;368:703-710.
68. Tschudi MR, Lüscher TF. Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins. Circulation 1995; 91:2415-2422.
69. Lüscher TF, Vanhoutto PM. Endothelium-dependent responses to platelets and serotonin in spontaneously hypertensive rats. Hypertension 1986; 8:II55-II60; [published erratum appears in Hypertension 1987; 9:421].
70. Tschudi MR, Mesaros S, Lüscher TF, Malinski T. Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension 1996; 27:32-35.
71. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97:2222-2229.
72. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992; 10:1025-1031.
73. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990, 323:22-27.
74. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997; 349:837-842.
75. Panza JA, Quyyumi AA, Callahan TS, Epstein SE. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993; 21:1145-1151.
76. Cockcroft JR, Chowienczyk PJ, Benjamin N, Rittor JM. Preserved endothelium-dependent vasodilation in patients with essential hypertension. N Engl J Med 1994; 330:1036-1040.
77. G-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol 1991; 261 (6 Pt 2):F1033-F1037.
78. Salazar FJ, Pinilla JM, Lopez F, Romero JC, Quesada T. Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide. Hypertension 1992; 20:113-117.
79. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
80. Lüscher TF, Seo BG, Buhler FR. Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension 1993; 21:752-757.
81. Vanhoutte PM. Other endothelium-derived vasoactive factors. Circulation 1993; 87:V-9-V-17.
82. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996; 28:652-655.
83. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, et al. Polar secretion of endothelin-1 by cultured endothelin cells. J Biol Chem 1992; 267:16066-16068.
84. McMahon EG, Palomo MA, Moore WM. Phosphoramidon blocks the pressor activity of big endothelin [1-39] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1991; 17 (suppl 7):S29-S33.
85. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M, et al. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci 1993; 52:717-724.
86. Haynes WG, Ferro CJ, O'Kane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93:1860-1870.
87. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998; 338:784-790.
88. Pernow J. Kaijser L, Lundberg JM, Ahlborg G. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996; 94:2077-2082.
89. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344:852-854.
90. Kaasjager KA, Koomans HA, Rabelink TJ. Endothelin-1 -induced vasopressor responses in essential hypertension. Hypertension 1997; 30:15-21.
91. Haynes WG, Moffat S, Webb DJ. An investigation into the direct and indirect venoconstrictor effects of endothelin-1 and big endothelin-1 in man. Br J Clin Pharmacol 1995; 40:307-311.
92. Noll G, Wenzel RR, Schneider M, Oesch V, Binggoli C, Shaw S, et al. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation 1996; 93:866-869.
93. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens 1997; 15:57-63.
94. Lüscher TF, Vanhoutte PM, Raij L. Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension 1987; 9 (6 Pt 2):III1 93-III1 97.
95. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Luscher TF. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation 1994; 89:2212-2218.
96. Dohi Y, Criscione L, Pfeiffer K, Lüscher TF. A blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesonteric resistance arteries. J Cardiovasc Pharmacol 1994; 24:372-379.
97. Feelisch M, Noack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987; 139:19-30.
98. Pohl U, Busse R. Endothelium-derivod relaxant factor inhibits effects of nitrocompounds in isolated arteries. Am J Physiol 1987; 252 (2 Pt 2):H307-H313.
99. Lüscher TF, Richard V, Yang ZH. Interaction between endothelium-derived nitric oxide and SIN-1 in human and porcine blood vessels. J Cardiovasc Pharmacol 1989; 14 (suppl 11):S76-S80.
100. Joannides R, Richard V, Haefeli WE, Linder L, Lüscher TF, Thuillez C. Role of basal and stimulated release of nitric oxide in the regulation of radial artery caliber in humans. Hypertension 1995; 26:327-331.
101. Sellke FW, Myers PR, Bates JN, Harrison DG. Influence of vessel size on the sensitivity of porcine coronary microvessels to nitroglycerin. Am J Physiol 1990; 258 (2 Pt 2):H515-H520.
102. 2+ antagonists. J Cardiovasc Pharmacol 1988; 12 (suppl 6):S21-S28.
103. Takase H, Moreau P, Kung CF, Nava E, Lüscher TF. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertension 1996; 27:25-31.
104. Kung CF, Moreau P, Takase H, Lüscher TF. L-NAME hypertension alters endothelial and smooth muscle function in rat aorta. Prevention by trandolapril and verapamil. Hypertension 1995; 26:744-751.
105. Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997; 30:1606-1612.
106. Taddei S, Virdis A, Ghiadoni L, Sudano I, Noll G, Lüscher TF, et al. Nifedipine enhances endothelium-dependent relaxations and inhibits contractions to endothelin-1 and phenilephrine in human hypertension [abstract]. Circulation 1997; 96 (suppl I):1-762-1-763.
107. Küng CF, Tschudi MR, Noll G, Clozel JP, Lüscher TF. Differential effects of the calcium antagonist mibefradil in epicardial and intramyocardial coronary arteries. J Cardiovasc Pharmacol 1995; 26:312-318.
108. Lupo E, Locher R, Weisser B, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha tocopherol. Biochem Biophys Res Commun 1994; 203:1803-1808.
109. Noll G, Buhler FR, Yang Z, Lüscher TF. Different potency of endothelium-derived relaxing factors against thromboxane, endothelin, and potassium chloride in intramyocardial porcine coronary arteries. J Cardiovasc Pharmacol 1991; 18:120-126.
110. 2+ channel in vascular smooth muscle. Proc Natl Acad Sci USA 1989; 86:3915-3918.
111. Yang Z, Bauer E, von Segesser L, Stulz P, Turina M, Lüscher TF. Different mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: effects of calcium antagonists. J Cardiovasc Pharmacol 1990; 16:654-660.
112. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
113. Wiemer G, Scholkens BA, Becker RH, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18:558-563.
114. Yang Z, Arnet U, von Segesser L, Siebenmann R, Turina M, Lüscher TF. Different effects of angiotensin-converting enzyme inhibition in human arteries and veins. J Cardiovasc Pharmacol 1993; 22 (suppl 5):S17-S22.
115. Auch Schwelk W, Bossaller C, Claus M, Graf K, Grafe M, Fleck E. Local potentiation of bradykinin-induced vasodilation by converting-enzyme inhibition in isolated coronary arteries. J Cardiovasc Pharmacol 1992; 20 (suppl 9):S62-S67.
116. Kahonen M, Makynen H, Wu X, Arvola P, Porsti I. Endothelial function in spontaneously hypertensive rats: influence of quinapril treatment. Br J Pharmacol 1995; 115:859-867.
117. Bossaller C, Auch-Schwelk W, Weber F, Gotze S, Grafe M, Graf K, et al. Endothelium-dependent relaxations are augmented in rats chronically treated with the angiotensin-converting enzyme inhibitor enalapril. J Cardiovasc Pharmacol 1992; 20 (suppl 9):S91-S95.
118. Schiffrin EL, Deng LY. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995; 25:699-703.
119. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258-265; [published erratum appears in Circulation 1996; 94:1490].
120. Mimran A, Ribstein J, DuCailar G. Contrasting effect of antihypertensive treatment on the renal response to L-arginine. Hypertension 1995;26:937-941.
121. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994; 24:499-505.
122. Kiowski W, Linder L, Nuesch R, Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension 1996;27;371-376.
123. Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998; 16:447-456.
124. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45:205-251.
125. d'Uscio LV, Shaw S, Barton M, Lüscher TF. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase. Hypertension 1998; 31:1305-1310.
126. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923.
127. Rodrigo E, Maeso R, Munoz-Garcia R, Navarro-Cid J, Ruilope LM, Cachofeiro V, et al. Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril, J Hypertens 1997; 15:613-618.
128. Baan J Jr, Chang PC, Vermeij P, Pfaffendorf M, van Zwioten PA. Effects of angiotensin II and losartan in the forearm of patients with essential hypertension. J Hypertens 1998; 16:1299-1305.
129. Richard V, Hogie M, Clozel M, Loffler BM, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995; 91:771-775.
130. Donckier J, Stoleru L, Hayashida W, Van Mechelen H, Selvais P, Galanti L, et al. Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 1995; 92:106-113.
131. Wenzel RR, Noll G, Lüscher TF. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994; 23:581-586.
132. Sütsch G, Fleisch M, Van X-W, Wenzel R, Binggeli C, Bianchetti MC, et al. Acute hemodynamic and renal effects of the endothelin-receptor antagonist TAK-044 in patients without heart failure [abstract]. J Am Coll Cardiol 1997; 29 (suppl A):444A.
133. Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998; 98:2235-2240.
134. d'Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Lüscher TF. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension 1997; 29:435-441.
135. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989; 3:145-151.
136. Graf K, Koehne P, Gräfe M, Zhang M, Auch-Schwelk W, Fleck E. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 1995; 26:230-235.
137. Dussaule JC, Stefanski A, Bea ML, Ronco P, Ardaillou R. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol 1993; 264 (1 Pt 2):F45-F52.
138. Stephenson SL, Kenny AJ. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 1987; 243:183-187.
139. Lang CC, Motwani JG, Coutie WJR, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor. Clin Sci 1992; 82:619-623.
140. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-54.11. Biochem J 1993; 291:83-88.
141. Skidgel RA, Engelbrecht S, Johnson AR, Erdos EG. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 1984; 5:769-776.
142. Murphy LJ, Corder R, Mallet AI, Turner AJ. Generation by the phosphoramidon-sensitive peptidases, endopeptidase 24.11 and thermolysin, of endothelin-1 and C-terminal fragment from big endothelin-1. Br J Pharmacol 1994; 113:137-142.
143. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998; 97:2323-2330.
144. Danilewicz JC, Barclay PL, Barnish IT, Brown D, Campbell SF, James K, et al. UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem Biophys Res Commun 1989; 164:58-65.
145. Schwartz JC, Gros C, Lecomte JM, Bralet J. Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications. Life Sci 1990; 47:1279-1297.
146. Gros C, Souque A, Schwartz J-C, Duchier J, Cournot A, Baumer P, et al. Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan. Proc Natl Acad Sci USA 1989; 86:7580-7584.
147. Northridge DB, Jardine AG, Alabaster CT, Barclay PL, Connell JMC, Dargie HJ, et al. Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet 1989; ii:591-593.
148. Richards AM, Wittert G, Espiner EA, Yandle TG, Frampton C, Ikram H. Prolonged inhibition of endopeptidase EC 24.11 in normal man: renal, endocrine and haemodynamic effects. J Hypertens 1991; 9:955-962.
149. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992; 10:607-613.
150. O'Connell JE, Jardine AG, Davies DL, McQueen J, Connell JMC. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. Clin Sci 1993; 85:19-26.
151. Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995; 26:1160-1166.
152. Richards AM, Crozier IG, Espiner EA, Yandle TG, Nicholls MG. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. Hypertension 1993; 22:231-236.
153. Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994; 7:943-947.
154. Fettner SH, Pai S, Zhu G-R, Kosoglou T, Banfield CR, Batra V. Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metallopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension. Eur J Clin Pharmacol 1995;48:351-359.
155. Singer DRJ, Markandu ND, Buckley MG, Miller MA, Sagnella GA, MacGregor GA. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension. Hypertension 1991; 18:798-804.
156. Kahn JC, Patoy M, Dubois-Rando JL, Morlet P, Castaigne A, Lim-Alexandre C, et al. Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 1990; 335:118-119.
157. Pham I, Gonzales W, EI Amrani A-IK, Fournié-Zaluski M-C, Philippe M, Laboulandine I, et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993; 265:1339-1347.
158. Fournié-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proc Natl Acad Sci USA 1994; 91:4072-4076.
159. Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR. In vivo pharmacology of dual neutral endopeptidase/angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1996; 28:672-678.
160. Tikkanen T, Tikkanen I, Rockell MD, Allen TJ, Johnston CI, Cooper ME, et al. Dual inhibition of neutral ondopoptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 1998; 32:778-785.
161. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998; 11:363-372.